Jacob Breaux, MD
Gastroenterology · Lafayette, LANPI 1437416617
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,055 of the $8,730 with a category attached, or 80.8%. 29 manufacturers reported payments, led by AbbVie at 33.8% of the total. Reporting peaked in 2022 at $2,122 and has fallen 59.2% since, to $867 in 2025.
Across 512 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Olympus Corporation$2K
- Johnson & Johnson$813
- Takeda Pharmaceuticals U.S.A., Inc.$672
- Bristol Myers Squibb$590
- Pfizer$479
- plus $2K from 23 others
Across 45 payments — averaging $8851.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$398K
What the payments were for
- Consulting fees$1,57518%
- Food & beverage$7,05581%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 225 | $2,947 |
| Olympus Corporation | 4 | $1,575 |
| Johnson & Johnson | 71 | $813 |
| Takeda Pharmaceuticals U.S.A., Inc. | 45 | $672 |
| Bristol Myers Squibb | 47 | $590 |
| Pfizer | 32 | $479 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $292 |
| Daiichi Sankyo Inc. | 7 | $155 |
| Medtronic | 4 | $153 |
| UCB, Inc. | 3 | $152 |
| Gilead | 7 | $145 |
| Ferring Pharmaceuticals Inc. | 8 | $130 |
| Ardelyx, Inc. | 5 | $96 |
| Merck | 6 | $85 |
| Nestle Healthcare Nutrition Inc. | 5 | $68 |
| Braintree Laboratories, Inc. | 5 | $64 |
| Intercept Pharmaceuticals, Inc. | 5 | $63 |
| Sanofi | 2 | $47 |
| Amgen | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Fresenius Kabi USA, LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $17 |
| Madrigal Pharmaceuticals | 1 | $16 |
| Enterra Medical, Inc. | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $15 |
| Olympus America Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,730 in reported general payments places this provider in the 75th percentile of 254 gastroenterology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 23 | $686,007 |
| Humira(Cf) PenAdalimumab | 12 | $81,712 |
| LinzessLinaclotide | 64 | $55,511 |
| Mesalamine | 45 | $13,777 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 188 | $12,236 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 54 | $9,152 |
| MotegrityPrucalopride Succinate | 15 | $8,714 |
| Dexlansoprazole DrDexlansoprazole | 20 | $7,059 |
| MovantikNaloxegol Oxalate | 17 | $6,721 |
| Colestipol Hcl | 93 | $6,305 |
| TrulancePlecanatide | 12 | $6,032 |
| Pantoprazole Sodium | 388 | $4,399 |
| Budesonide DrBudesonide | 22 | $3,460 |
| Omeprazole | 295 | $3,114 |
| Rabeprazole Sodium | 53 | $2,614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $813 | $686,00723 claims |
| AbbVieLinzess | $2,947 | $55,51164 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $130 | $9,15254 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $672 | $8,71415 claims |
| Redhill Biopharma Inc.Movantik | $15 | $6,72117 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $292 | $6,03212 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $23 | $5715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 254 gastroenterology providers in Louisiana.
Other gastroenterology in Lafayette
- Eric TrawickLafayette$54K
- Erick SalvatierraLafayette$27K
- Jacque NoelLafayette$12K
- Jacob KarrLafayette$10K
- Jonathon ChapmanBaton Rouge$998K
- Conar FittonKenner$955K
- Gia LandryBaton Rouge$511K
- Charles MonierThibodaux$448K
- Nathaniel RanneyCovington$392K
- Georges CatinisMetairie$346K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.